Aaron MBA - GH Research Chief Officer
| GHRS Stock | USD 9.10 0.01 0.11% |
Executive
Aaron MBA is Chief Officer of GH Research PLC
| Age | 39 |
| Address | Joshua Dawson House, Dublin, Ireland, D02 RY95 |
| Phone | 353 1 437 8334 |
| Web | https://www.ghres.com |
GH Research Management Efficiency
The company has return on total asset (ROA) of (0.1274) % which means that it has lost $0.1274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.162) %, meaning that it created substantial loss on money invested by shareholders. GH Research's management efficiency ratios could be used to measure how well GH Research manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.17 in 2024. Return On Capital Employed is likely to drop to -0.2 in 2024. Total Assets is likely to drop to about 168.7 M in 2024. Net Tangible Assets is likely to drop to about 146.6 M in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jennifer MBA | Arcus Biosciences | 53 | |
| Shikhar MBA | Annexon | N/A | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Jamie MD | Annexon | 66 | |
| MD MBA | Molecular Partners AG | N/A | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Alexander Constan | Ikena Oncology | N/A | |
| Arthur Hanson | Champions Oncology | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Mahesh Padval | Relay Therapeutics | N/A | |
| Brenda Vreeswyk | Janux Therapeutics | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| Hui Lei | Structure Therapeutics American | N/A | |
| Michael Covarrubias | Rezolute | N/A | |
| Eric Hoefer | Arcus Biosciences | N/A | |
| Xinglong Jiang | Structure Therapeutics American | N/A | |
| Crystal Zuckerman | Pmv Pharmaceuticals | N/A | |
| Valdas Jurkauskas | Ikena Oncology | N/A | |
| CPA CFA | Janux Therapeutics | 48 | |
| Stephen Young | Arcus Biosciences | 55 | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.13 |
GH Research PLC Leadership Team
Elected by the shareholders, the GH Research's board of directors comprises two types of representatives: GH Research inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GHRS. The board's role is to monitor GH Research's management team and ensure that shareholders' interests are well served. GH Research's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GH Research's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie ACA, VP Fin | ||
| Magnus Halle, CoFounder Ireland | ||
| Naoise Gaffney, VP Property | ||
| Velichka MD, Chief Officer | ||
| Florian M, CoFounder Chairman | ||
| Theis MD, CoFounder CEO | ||
| Aaron MBA, Chief Officer | ||
| Julie FCA, Vice Finance |
GHRS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GH Research a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 324.15 M | ||||
| Shares Outstanding | 52.03 M | ||||
| Shares Owned By Insiders | 40.38 % | ||||
| Shares Owned By Institutions | 59.15 % | ||||
| Number Of Shares Shorted | 1.91 M | ||||
| Price To Book | 2.50 X | ||||
| EBITDA | (41.15 M) | ||||
| Net Income | (35.59 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GHRS Stock Analysis
When running GH Research's price analysis, check to measure GH Research's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GH Research is operating at the current time. Most of GH Research's value examination focuses on studying past and present price action to predict the probability of GH Research's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GH Research's price. Additionally, you may evaluate how the addition of GH Research to your portfolios can decrease your overall portfolio volatility.